2590-2571

Current Research in Pharmacology and Drug Discovery

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 245 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact245 DOIs
2

Attach ORCID iDs across 66 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact66 DOIs
3

Deposit reference lists for 25 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact25 DOIs

DOIs for this ISSN

Showing the top 5 of 245 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Role of pro-inflammatory cytokines in Alzheimer's disease an… (10.1016/j.crphar.2022.100149)
Abstract ORCID
96.47 84
2 Therapeutics for COVID-19 and post COVID-19 complications: A… (10.1016/j.crphar.2022.100086)
Abstract ORCID
90.31 63
3 Indole: A promising scaffold for the discovery and developme… (10.1016/j.crphar.2022.100119)
Abstract ORCID
87.41 55
4 Emerging roles of cardamonin, a multitargeted nutraceutical… (10.1016/j.crphar.2020.100008)
Abstract ORCID
84.95 49
5 GSK2606414 attenuates PERK/p-eIF2α/ATF4/CHOP axis and augmen… (10.1016/j.crphar.2022.100087)
Abstract ORCID
84.95 49
6 Plant metabolite diosmin as the therapeutic agent in human d… (10.1016/j.crphar.2022.100122)
Abstract ORCID
84.51 48
7 Sex differences in drug effects and/or toxicity in oncology (10.1016/j.crphar.2022.100152)
Abstract ORCID
84.06 47
8 Host directed therapies: COVID-19 and beyond (10.1016/j.crphar.2021.100058)
Abstract ORCID
82.66 44
9 Pretomanid for tuberculosis treatment: an update for clinica… (10.1016/j.crphar.2022.100128)
Abstract ORCID
74.57 30
10 Can the application of graphene oxide contribute to the figh… (10.1016/j.crphar.2021.100062)
Abstract ORCID
72.36 27
11 Pharmacological interactions: Synergism, or not synergism, t… (10.1016/j.crphar.2021.100046)
Abstract ORCID
68.09 22
12 Cyclodextrin-based therapeutics delivery systems: A review o… (10.1016/j.crphar.2025.100232)
Abstract ORCID
66.11 20
13 Hypoxia may be a determinative factor in COVID-19 progressio… (10.1016/j.crphar.2021.100030)
Abstract ORCID
65.05 19
14 Gauging the role and impact of drug interactions and repurpo… (10.1016/j.crphar.2021.100022)
Abstract ORCID
62.76 17
15 Evaluation of synergism in drug combinations and reference m… (10.1016/j.crphar.2022.100110)
Abstract
61.56 289
16 Anti-emetic effects of thalidomide: Evidence, mechanism of a… (10.1016/j.crphar.2022.100138)
Abstract ORCID
61.52 16
17 Application of coating technology to chronotherapeutic drug… (10.1016/j.crphar.2021.100015)
Abstract ORCID
58.80 14
18 Regulation of biofilm formation by non-coding RNA in prokary… (10.1016/j.crphar.2022.100151)
Abstract ORCID
58.80 14
19 Synthesis, molecular docking, and biological evaluation of S… (10.1016/j.crphar.2021.100024)
Abstract ORCID
57.31 13
20 Amelioration of experimentally induced inflammatory arthriti… (10.1016/j.crphar.2022.100114)
Abstract ORCID
57.31 13
21 Liraglutide improves adipose tissue remodeling and mitochond… (10.1016/j.crphar.2024.100185)
Abstract ORCID
57.31 13
22 Enhanced antihyperlipidemic potential of gemfibrozil under c… (10.1016/j.crphar.2021.100021)
Abstract ORCID
55.70 12
23 An updated review on potential therapeutic drug candidates,… (10.1016/j.crphar.2021.100063)
Abstract ORCID
55.70 12
24 The relationship between gender and pharmacology (10.1016/j.crphar.2024.100192)
Abstract ORCID
55.70 12
25 Flavonoids as promising molecules in the cancer therapy: An… (10.1016/j.crphar.2023.100167)
Abstract
52.25 122
26 Progress towards a clinically-successful ATR inhibitor for c… (10.1016/j.crphar.2021.100017)
Abstract
52.16 121
27 Pharmacodynamic evaluation of the XOR inhibitor WN1703 in a… (10.1016/j.crphar.2022.100098)
Abstract ORCID
52.07 10
28 Teriflunomide: A possible effective drug for the comprehensi… (10.1016/j.crphar.2021.100055)
Abstract
46.88 74
29 New paradigm in combination therapy of siRNA with chemothera… (10.1016/j.crphar.2022.100103)
Abstract
44.98 62
30 Coumarin: A natural solution for alleviating inflammatory di… (10.1016/j.crphar.2024.100202)
Abstract
44.98 62
31 Anti-inflammatory potential of quercetin: From chemistry and… (10.1016/j.crphar.2025.100217)
Abstract
44.98 62
32 The therapeutic potential of carnosine: Focus on cellular an… (10.1016/j.crphar.2023.100153)
Abstract
43.90 56
33 Tuberculosis: Past, present and future of the treatment and… (10.1016/j.crphar.2021.100037)
Abstract
43.70 55
34 Activity-based protein profiling: A graphical review (10.1016/j.crphar.2023.100164)
Abstract
43.70 55
35 Exploring new Horizons in overcoming P-glycoprotein-mediated… (10.1016/j.crphar.2021.100054)
Abstract
43.51 54
36 Artificial intelligence-driven drug repurposing and structur… (10.1016/j.crphar.2021.100042)
Abstract
43.11 52
37 Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpr… (10.1016/j.crphar.2021.100038)
Abstract
42.47 49
38 Reversal of TGF-β-induced epithelial–mesenchymal transition… (10.1016/j.crphar.2021.100014)
Abstract ORCID
42.25 6
39 The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine… (10.1016/j.crphar.2024.100195)
Abstract ORCID
42.25 6
40 Tocotrienols-rich naringenin nanoemulgel for the management… (10.1016/j.crphar.2021.100019)
Abstract
42.03 47
41 Crosstalk between anticancer drugs and mitochondrial functio… (10.1016/j.crphar.2021.100047)
Abstract
42.03 47
42 Pathophysiology and possible treatments for olfactory-gustat… (10.1016/j.crphar.2021.100035)
Abstract
41.80 46
43 Inhalation potential of N-Acetylcysteine loaded PLGA nanopar… (10.1016/j.crphar.2022.100084)
Abstract
41.57 45
44 Positioning biologics in the treatment of IBD: A practical g… (10.1016/j.crphar.2022.100104)
Abstract
41.33 44
45 Prostate cancer: Therapeutic prospect with herbal medicine (10.1016/j.crphar.2021.100034)
Abstract
40.84 42
46 Systematic review on role of structure based drug design (SB… (10.1016/j.crphar.2021.100026)
Abstract
38.91 35
47 GERD: Latest update on acid-suppressant drugs (10.1016/j.crphar.2024.100198)
Abstract ORCID
38.91 5
48 Comparison of anti-SARS-CoV-2 activity and intracellular met… (10.1016/j.crphar.2021.100045)
Abstract
37.96 32
49 Unmet needs in inflammatory bowel disease (10.1016/j.crphar.2021.100070)
Abstract
37.96 32
50 Supramolecular lipid nanoparticles as delivery carriers for… (10.1016/j.crphar.2021.100067)
Abstract
37.63 31